Current Report Filing (8-k)
May 07 2014 - 4:21PM
Edgar (US Regulatory)
|
|
|
UNITED
STATES
|
SECURITIES
AND EXCHANGE COMMISSION
|
Washington, D.C. 20549
|
|
|
|
|
|
|
FORM 8-K
|
|
|
|
|
|
|
CURRENT
REPORT
|
|
PURSUANT
TO SECTION 13 OR 15(d) OF
|
THE
SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
Date of Report (date of earliest event reported): May 6,
2014
|
|
|
|
|
|
|
|
Urologix,
Inc.
|
|
(Exact name of Registrant as Specified in its Charter)
|
|
|
|
|
Minnesota
|
|
(State Or Other Jurisdiction Of Incorporation)
|
|
|
|
|
|
|
|
000-28414
|
|
|
41-1697237
|
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification No.)
|
|
|
|
|
|
|
|
14405 21st Avenue North
|
|
|
|
|
|
Minneapolis, MN
|
|
|
55447
|
|
(Address Of Principal Executive Offices)
|
|
(Zip Code)
|
|
|
|
|
|
(763) 475-1400
|
|
Registrants Telephone Number, Including Area Code
|
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
|
|
|
|
o
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
o
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Items under
Sections 1 and 3 through 8 are not applicable and therefore omitted.
|
|
ITEM 2.02
|
RESULTS OF OPERATIONS AND
FINANCIAL CONDITION.
|
Urologix, Inc.
(the Company) hereby furnishes as Exhibit 99.1 a press release issued on May
6, 2014 disclosing material non-public information regarding the Companys
results of operations for the third fiscal quarter of fiscal year 2014 ended
March 31, 2014.
|
|
ITEM 9.01
|
FINANCIAL STATEMENTS AND EXHIBITS.
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press
Release issued on May 6, 2014.
|
SIGNATURE
Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned, hereunto
duly authorized.
|
|
|
|
|
UROLOGIX,
INC.
|
|
|
|
|
|
|
By:
|
/s/ Brian J.
Smrdel
|
|
|
|
Brian J.
Smrdel
|
|
|
|
Chief
Financial Officer
|
|
|
|
|
|
Date: May 7,
2014
|
|
|
|
Urologix (CE) (USOTC:ULGX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Urologix (CE) (USOTC:ULGX)
Historical Stock Chart
From Jul 2023 to Jul 2024